Cornea/External Disease News

Vevye, a preservative-free, twice-daily 0.1% cyclosporine ophthalmic solution indicated for treatment of signs and symptoms of dry eye disease, is now available in the U.S., according to a manufacturer press release.

Two pivotal phase 3 clinical trials evaluating the efficacy and safety of AR-15512 for treating the signs and symptoms of dry eye disease achieved the primary endpoint, according to a press release from Alcon.

Corneal ulcers are one of the fastest ways our patients with healthy eyes can quickly lose vision, but they’re also easy for any clinician with a slit lamp to identify.

Okyo Pharma announced positive safety and efficacy data from its phase 2 trial of OK-101 ophthalmic solution, a lipid-conjugated chemerin peptide agonist designed to reduce pain and inflammation in patients with dry eye disease.

The top Healio blogs in ophthalmology last year explored the future of drug prices in the wake of the Inflation Reduction Act and important tips for avoiding Stark Law violations.

NEW YORK — In a presentation at OSN New York, Kourtney Houser, MD, discussed the importance of optimizing the cornea before premium cataract surgery.

Harrow announced three partnerships to support the upcoming launch of Vevye, indicated for treating the signs and symptoms of dry eye disease.

Stuart Therapeutics has announced the first patient first visit for its phase 3 clinical trial of ST-100 ophthalmic solution for patients with dry eye disease.

Keratoconus may be associated with ADHD in male patients, according to a study recently published in JAMA Ophthalmology.

The top Healio cornea-related articles in 2023 included the FDA approval of Vevye for dry eye disease and the efficacy of azithromycin in the treatment of meibomian gland dysfunction.